A collision of timing
Perimenopause typically begins in the mid-forties and can run for a decade. That decade is, for most senior women, the one in which they hold the widest span of responsibility they will ever hold. The transition does not arrive at a convenient career stage. It arrives at the most consequential one.
This is not a story about decline. It is a story about timing, and about the fact that the standard advice was designed for a woman with fewer irreversible decisions in her diary.
What actually shows up at work
The symptoms that reach the boardroom are rarely the ones in the public conversation. Disrupted sleep does not present as a menopause symptom, it presents as a person who is less sharp in the afternoon. Changes in thermoregulation do not present as a symptom either, they present as someone who stops speaking in a long meeting. Shifts in working memory present as a leader who now writes everything down and quietly doubts herself for needing to.
Each of those is legible as a performance change and illegible as a physiological one, which is precisely why it gets attributed to the person rather than the transition.
Why it is handled privately, and why that is expensive
A senior woman weighing whether to raise this is not being coy. She is making a rational calculation about how the information will be used, in an environment where she may already be the only woman at her level, and where the vocabulary available to describe it is medical rather than operational.
So it gets managed alone. The organisational cost of that is not the symptom, it is the years of accumulated workaround, and eventually the departure that gets recorded as a lifestyle choice.
What a useful answer looks like
A useful answer is not a policy document and it is not a talk. It is a working knowledge of what is happening physiologically, which of the available interventions have evidence behind them and which are being marketed hard, and a way to make decisions about your own body with the same rigour you would apply to a capital allocation.
It also needs somewhere to have the conversation with peers at the same level, because the isolation is doing as much damage as the biology.
Where this goes next
The Female CEO Operating System is built around this specific collision rather than treating female biology as a variant of a male default. Judith Mueller leads that curriculum.
The programme covers what this article deliberately does not: the clinical detail, what the evidence supports at each stage, and how to construct a protocol you can defend to your own clinician.
This article is the public half. The Female CEO Operating System is where the rest of it lives.